ArticleScientific reports2016
Amicoumacin A induces cancer cell death by targeting the eukaryotic ribosome.
Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Straightforward Synthetic Approach to Aminoalcohols with 9-oxabicyclo[3.3.1]nonane or Cyclooctane Core via Nucleophilic Ring-Opening of Spirocyclic Bis(oxiranes).Molecules (Basel, Switzerland) · 2026Article
- Decoding the regulatory role of AmiC in amicoumacins production through transcriptomics and metabolic profiling in Bacillus subtilis fmb60.World journal of microbiology & biotechnology · 2026Article
- Evolution of ribosome X-ray crystallography: from first crystals to atomic resolution.Biophysical reviews · 2025Review
- Amicoumacins produced by the native citrus microbiome isolateApplied and environmental microbiology · 2025Article
- Mechanism of read-through enhancement by aminoglycosides and mefloquine.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- The Interplay Between theInternational journal of molecular sciences · 2024Review
- Synthetic macrolides overcoming MLSCell discovery · 2024Article
- Concentration and time-dependent amyloidogenic characteristics of intrinsically disordered N-terminal region ofFrontiers in microbiology · 2023Article
- Sparsomycin Exhibits Potent Antiplasmodial Activity In Vitro and In Vivo.Pharmaceutics · 2022Article
- Inhibition of the Eukaryotic 80S Ribosome as a Potential Anticancer Therapy: A Structural Perspective.Cancers · 2021Review
- Multifaceted Mechanism of Amicoumacin A Inhibition of Bacterial Translation.Frontiers in microbiology · 2021Article
- A Quick Guide to Small-Molecule Inhibitors of Eukaryotic Protein Synthesis.Biochemistry. Biokhimiia · 2020Review
- Tetracenomycin X inhibits translation by binding within the ribosomal exit tunnel.Nature chemical biology · 2020Article
- Hetiamacin E and F, New Amicoumacin Antibiotics fromMolecules (Basel, Switzerland) · 2020Article
- Deep Functional Profiling Facilitates the Evaluation of the Antibacterial Potential of the Antibiotic Amicoumacin.Antibiotics (Basel, Switzerland) · 2020Article
- Functional Cyclization of Eukaryotic mRNAs.International journal of molecular sciences · 2020Article
- Subcellular Performance of Nanoparticles in Cancer Therapy.International journal of nanomedicine · 2020Review
- Mechanism of the Potential Therapeutic CandidateFrontiers in microbiology · 2020Article
- Understanding the role of intermolecular interactions between lissoclimides and the eukaryotic ribosome.Nucleic acids research · 2019Article
- Tma64/eIF2D, Tma20/MCT-1, and Tma22/DENR Recycle Post-termination 40S Subunits In Vivo.Molecular cell · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Amicoumacin A is an antibiotic that was recently shown to target bacterial ribosomes. It affects translocation and provides an additional contact interface between the ribosomal RNA and mRNA. The binding site of amicoumacin A is formed by universally conserved nucleotides of rRNA. In this work, we showed that amicoumacin A inhibits translation in yeast and mammalian systems by affecting translation elongation. We determined the structure of the amicoumacin A complex with yeast ribosomes at a resolution of 3.1 Å. Toxicity measurement demonstrated that human cancer cell lines are more susceptible to the inhibition by this compound as compared to non-cancerous ones. This might be used as a starting point to develop amicoumacin A derivatives with clinical value.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.